Literature DB >> 1290306

On the role of Ca++ binding proteins as possible targets for Ca++ sensitizing agents.

J W Herzig1, U Quast.   

Abstract

We describe the effects of various cardioactive compounds on the Ca++ activation of force production and ATPase activity in isolated contractile structures from mammalian heart and, in some cases, skeletal muscle. We show that: 1) the Ca++ sensitizing activity of APP 201-533 does not discriminate between cardiac and skeletal muscle and is, therefore, not based on interaction with cardiac troponin I phosphorylation at serine 20. 2) compounds like trifluoperazine or bepridil, both known to interact with calmodulin, increase the Ca++ sensitivity of the contractile structures of the heart, in high concentrations, as expected from the high natural abundance of troponin C. 3) DPI 201-106 interacts with calmodulin (and presumably with the structurally closely related troponin C) in the microM concentration range. Its high Ca(++)-sensitizing potency in skinned cardiac muscle and a certain sensitivity of this effect to the detergent Triton X-100 suggest accumulation of the hydrophobic compound in the myofibrillar protein lattice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1290306

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  3 in total

1.  The role of the Ca(2+) regulatory sites of skeletal troponin C in modulating muscle fibre reactivity to the Ca(2+) sensitizer bepridil.

Authors:  P Kischel; B Bastide; J D Potter; Y Mounier
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts.

Authors:  A F Rump; D Acar; W Klaus
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

3.  Differential effects of bepridil on functional properties of troponin C in slow and fast skeletal muscles.

Authors:  P Kischel; L Stevens; Y Mounier
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.